The NRF2 transcription factor is one of the main regulators of the genes involved in the antioxidant response, including xCT. In breast cancer cells, the NRF2-dependent transcription of xCT can be inhibited by a direct interaction of NRF2 with mutant P53 proteins (Lisek et al., 2018); as a consequence, breast tumor cells with a P53 mutant protein may present low levels of xCT expression, resulting in low GSH and high ROS levels (Liu et al., 2017). This evidence concerns the gene SLC7A11 and breast neoplasm.